These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
98 related articles for article (PubMed ID: 8103740)
1. Evolving Issues in the Treatment of Ischaemic Heart Disease: The Potassium Channel Openers. Symposium proceedings. Barcelona, Spain, 2 September 1992. Eur Heart J; 1993 Jul; 14 Suppl B():1-52. PubMed ID: 8103740 [No Abstract] [Full Text] [Related]
2. Potassium channel openers: clinical applications in ischemic heart disease--overview of clinical efficacy of nicorandil. Knight C; Purcell H; Fox K Cardiovasc Drugs Ther; 1995 Mar; 9 Suppl 2():229-36. PubMed ID: 7647027 [TBL] [Abstract][Full Text] [Related]
3. Evolving Issues in the Treatment of Angina Pectoris. Nicorandil: The 1st Potassium-Channel Activator in Ischemic Heart Disease. Proceedings of an International Workshop. Taormina, Sicily, May 8-12, 1991. J Cardiovasc Pharmacol; 1992; 20 Suppl 3():S1-108. PubMed ID: 1282167 [No Abstract] [Full Text] [Related]
11. [Potassium channel activators: hemodynamic effects at the systemic and coronary level]. Perrone Filardi P; Chiariello M Cardiologia; 1995 Dec; 40(12 Suppl 1):87-9. PubMed ID: 8998787 [No Abstract] [Full Text] [Related]
12. [Anti-angina activity of potassium-channel activators]. Chiariello M; Duilio C; Ambrosio G Cardiologia; 1993 Dec; 38(12 Suppl 1):459-63. PubMed ID: 8020048 [TBL] [Abstract][Full Text] [Related]
13. [Potassium agonists]. Hellwig B Med Monatsschr Pharm; 1994 Jun; 17(6):164-7. PubMed ID: 8052166 [No Abstract] [Full Text] [Related]
14. Potassium channel activators in the management of ischaemic heart disease: a focus on nicorandil. Purcell H; Fox K Br J Clin Pract; 1993; 47(3):150-4. PubMed ID: 8347442 [TBL] [Abstract][Full Text] [Related]
15. Potassium channels as pharmacological targets in cardiovascular medicine. Escande D; Henry P Eur Heart J; 1993 Jul; 14 Suppl B():2-9. PubMed ID: 8370367 [TBL] [Abstract][Full Text] [Related]
16. Is potassium channel opening an effective form of preconditioning before cardioplegia? Menasché P; Mouas C; Grousset C Ann Thorac Surg; 1996 Jun; 61(6):1764-8. PubMed ID: 8651781 [TBL] [Abstract][Full Text] [Related]
17. Early afterdepolarization abolished by potassium channel opener in a patient with idiopathic long QT syndrome. Sato T; Hata Y; Yamamoto M; Morita H; Mizuo K; Yamanari H; Saito D; Ohe T J Cardiovasc Electrophysiol; 1995 Apr; 6(4):279-82. PubMed ID: 7647953 [TBL] [Abstract][Full Text] [Related]
18. Pinacidil but not nicorandil opens ATP-sensitive K+ channels and protects against simulated ischemia in rabbit myocytes. Critz SD; Liu GS; Chujo M; Downey JM J Mol Cell Cardiol; 1997 Apr; 29(4):1123-30. PubMed ID: 9160864 [TBL] [Abstract][Full Text] [Related]
19. Improvement of repolarization abnormalities by a K+ channel opener in the LQT1 form of congenital long-QT syndrome. Shimizu W; Kurita T; Matsuo K; Suyama K; Aihara N; Kamakura S; Towbin JA; Shimomura K Circulation; 1998 Apr; 97(16):1581-8. PubMed ID: 9593563 [TBL] [Abstract][Full Text] [Related]
20. [Ca-antagonist, K-channel-opener in the treatment of patients with congestive heart failure]. Satoh K Nihon Rinsho; 1993 May; 51(5):1293-8. PubMed ID: 8331797 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]